Unicycive Therapeutics Investors Encouraged to Join Class Action Lawsuit

Investors Alert: Class Action Lawsuit Against Unicycive Therapeutics

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) has come under scrutiny as The Gross Law Firm has announced a potential class action lawsuit focused on shareholders who have faced financial losses. Recent allegations from the firm indicate that the company misrepresented its capabilities and regulatory standing with the FDA, leading to misleading public statements that allegedly inflated the stock price.

Overview of the Situation

The Gross Law Firm is actively reaching out to shareholders who purchased UNCY shares between March 29, 2024, and June 27, 2025. The law firm emphasizes that those affected by potential stock manipulation are urged to register for more information about the class action proceedings. Importantly, registration does not obligate the investor to serve as a lead plaintiff.

Allegations Against Unicycive Therapeutics

The core of the lawsuit revolves around claims that the company overstated its readiness to meet FDA manufacturing compliance standards. Furthermore, key segments of their new drug application for oxylanthanum carbonate were allegedly presented with inflated prospects of regulatory approval. As such, investors may find that statements made by Unicycive during the class period were not only misleading but materially false, causing significant financial implications for shareholders.

Important Deadlines for Investors

Shareholders looking to participate in the class action should not hesitate. The deadline to register as a lead plaintiff is set for October 14, 2025. Those interested can easily register using the provided online form associated with The Gross Law Firm, which assures participants of a transparent process, complete with updates throughout the legal journey.

Why Choose The Gross Law Firm?

The Gross Law Firm has positioned itself as a prominent advocate for investor rights, especially in class action cases involving allegations of fraud, deceit, and misleading company practices. With a national reputation for protecting the interests of shareholders, the firm aims to recover losses incurred by investors due to corporate misconduct. Their commitment ensures that companies like Unicycive are held accountable for their public disclosures and business practices.

Next Steps for Affected Shareholders

Affected shareholders are encouraged to take quick actions to secure their potential recovery. By registering, they will gain access to portfolio monitoring software, which will provide real-time updates on the progress of the case. Importantly, there is no cost associated with registering, thus allowing investors to seek legal guidance without financial commitment.

Conclusion

If you have lost money as a result of investments in Unicycive Therapeutics, you are not alone. Reach out to The Gross Law Firm to discuss your rights and explore the possibility of joining this class action lawsuit. By standing together, investors can potentially restore losses incurred due to misleading practices from the company.

Contact Details:
The Gross Law Firm, based in New York, can be reached through email at [email protected], or by phone at (646) 453-8903, for those wishing to inquire about their rights in this matter.